GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been assigned an average recommendation of “Hold” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $3.8542.

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group lowered shares of GoodRx to a “hold” rating in a report on Thursday, January 22nd. Wells Fargo & Company lowered their target price on shares of GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Wall Street Zen lowered shares of GoodRx from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GoodRx in a research note on Friday, February 27th. Finally, Citigroup decreased their price objective on shares of GoodRx from $4.50 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, March 3rd.

GoodRx Trading Up 2.4%

GDRX opened at $2.56 on Wednesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.61 and a quick ratio of 2.61. GoodRx has a fifty-two week low of $1.77 and a fifty-two week high of $5.81. The firm has a market capitalization of $876.98 million, a PE ratio of 28.45, a P/E/G ratio of 1.73 and a beta of 1.54. The company’s 50-day moving average is $2.19 and its 200 day moving average is $2.60.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Wednesday, February 25th. The company reported $0.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.09. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The company had revenue of $194.79 million for the quarter, compared to analyst estimates of $193.27 million. During the same quarter in the prior year, the business posted $0.09 EPS. The firm’s revenue was down 1.9% compared to the same quarter last year. As a group, research analysts predict that GoodRx will post 0.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GoodRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in GoodRx in the 3rd quarter valued at about $33,000. Cetera Investment Advisers purchased a new stake in GoodRx in the 2nd quarter valued at about $50,000. Boothbay Fund Management LLC purchased a new stake in GoodRx in the 3rd quarter valued at about $43,000. Meridian Wealth Management LLC purchased a new stake in GoodRx in the 4th quarter valued at about $29,000. Finally, Shay Capital LLC purchased a new stake in GoodRx in the 3rd quarter valued at about $47,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.